Fig. 2: Differences in membrane fatty acid levels and ratios between patients with schizophrenia at baseline (SZ-0) and healthy controls (HC) as well as changes after antipsychotic treatment (SZ-4). | Schizophrenia

Fig. 2: Differences in membrane fatty acid levels and ratios between patients with schizophrenia at baseline (SZ-0) and healthy controls (HC) as well as changes after antipsychotic treatment (SZ-4).

From: Reduced erythrocyte membrane polyunsaturated fatty acid levels indicate diminished treatment response in patients with multi- versus first-episode schizophrenia

Fig. 2

a Specific fatty acids we measured and summations for SFAs, n-6 PUFAs, n-3 PUFAs, PUFAs, and total FAs; b n-6/n-3 ratio, omega-3 index and unsaturation index; c fatty acid ratios (markers of enzymes). SFAs, saturated fatty acids; PUFAs, polyunsaturated fatty acids; FAs, fatty acids; plots are shown as the means and standard errors; the Mann–Whitney test was used to analyze the variations between HC and SZ-0, and group pairwise differences between SZ-0 and SZ-4 were determined by the Wilcoxon signed rank test. *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page